IOVA

Iovance Biotherapeutics, Inc. is a pioneering clinical-stage biotechnology firm based in San Carlos, California, specializing in innovative cancer immunotherapy through its proprietary tumor-infiltrating lymphocyte (TIL) therapy. This cutting-edge approach leverages the patient’s immune system to target and treat various malignancies, with a primary focus on melanoma and cervical cancer. With a promising pipeline and commitment to scientific excellence, Iovance is well-positioned to address significant unmet medical needs in oncology, making it an appealing investment in the expanding field of cancer therapeutics.